Net survival in recurrence-free colon cancer patients. (August 2019)

• Record Type: Journal Article
• Authors: Drouillard, Antoine; Bouvier, Anne-Marie; Boussari, Olayidé; Romain, Gaëlle; Manfredi, Sylvain; Lepage, Come; Faivre, Jean; Jooste, Valérie
• Is Part Of: Cancer epidemiology. Volume 61(2019:Aug.)
• Page Start: 124
• Page End: 128
• Publication Date: 2019-08
• Subjects: CNS-RF Conditional Net Survival in Recurrence-Free patients; Colon cancer -- Conditional net survival -- Recurrence-free -- Population-based study -- Cancer registry; Cancer -- Epidemiology -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Diagnosis -- Periodicals; Carcinogenesis -- Periodicals; 616.994005
• DOI: 10.1016/j.canep.2019.06.001
• Languages: English
• ISSNs: 1877-7821

Abstract

Highlights: Conditional net survival for recurrence-free cancer survivors (CNS-RF) is innovative. It allows clinicians providing objective reassuring information to patients. Whatever the stage at diagnosis, 5-year CNS-RF was > 90% for colon cancer patients. It was > 95% in patients diagnosed after 2000 and recurrence-free after 3 years. This should be used to facilitate access to credit or insurance for cancer survivors. Abstract: Purpose: Conditional net survival in recurrence-free patients (CNS-RF) provides relevant clinical information and has never been assessed yet in a non-selected colon cancer population. We aimed to estimate conditional 5-year net survival in recurrence-free patients with colon cancer in the population-based Digestive Cancer Registry of Burgundy (France). Methods: CNS-RF was estimated in the 3736 patients resected for cure for primary colon cancer between 1976 and 2006, using a flexible parametric model of net survival for every additional year survived at diagnosis and from 1 to 5 years thereafter. Results: The net probability of surviving 5 more years increased from 72% at diagnosis to 92% for recurrence-free patients who survived 5 years after diagnosis. CNS-RF was over 90% 3 years after diagnosis in patients aged 75 and below. CNS-RF was over 95% in patients diagnosed after 2000 who were recurrence-free 3, 4 or 5 years after diagnosis. CNS-RF was similar between patients with stage I and II disease from 2 years after diagnosis and patients with stage III disease from 5 years after diagnosis. The initial differences in net survival related to gross features, clinical presentation, number of harvested nodes in stage II, and number of involved nodes in stage III disappeared after 2 years. Conclusions: CNS-RF is a relevant measure of prognosis in patients who have already achieved a period of remission. Providing an updated estimation of prognosis in the years following diagnosis may improve the survivors' quality of life and access to credit or insurance.